Off-the-Shelf CAR t cells show promise for tough lymphomas

NCT ID NCT03939026

First seen Nov 05, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This early-phase study tested a new type of cancer treatment called ALLO-501, which is a 'off-the-shelf' CAR T cell therapy made from donor cells. It was given to 50 adults with large B-cell lymphoma or follicular lymphoma that had come back or stopped responding to at least two prior treatments. The goal was to check the treatment's safety and how well it worked, using a special drug (ALLO-647) to help prepare the body. While not a cure, this approach aims to control the disease without needing lifelong medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, 85234, United States

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • MD Anderson

    Houston, Texas, 77030, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40207, United States

  • St. Davids South Austin Medical Center

    Austin, Texas, 78704, United States

  • Stanford University

    Stanford, California, 94305, United States

Conditions

Explore the condition pages connected to this study.